title: Retrospective Analysis on the Feasibility and Efficacy of Docetaxel-Cisplatin Therapy for Recurrent Endometrial Cancer.
abstract: OBJECTIVE
  There is poor evidence regarding effective treatment for recurrent endometrial cancer. We treated patients with recurrent endometrial cancer with docetaxel-cisplatin (DP) therapy as second-line or third-line chemotherapy. We aimed to evaluate the feasibility and efficacy of DP therapy for patients with recurrent endometrial cancer.
  
  
  METHODS
  We included 26 patients diagnosed with recurrent endometrial cancer, who underwent DP chemotherapy at our Institution. Docetaxel at 70 mg/m(2)and cisplatin at 60 mg/m(2)were administered by intravenous injection every 3 weeks. We retrospectively analyzed the clinicopathological factors associated with the response rate (RR) and prognosis. We also analyzed the adverse effects of DP therapy.
  
  
  RESULTS
  Median follow-up was 33.8 months and the median number of therapy cycles was six. Grade 3 or 4 adverse effects included leukopenia (66%), neutropenia (81%), anemia (9%), diarrhea (12%), general fatigue (12%), liver dysfunction (4%), peripheral neuropathy (4%), and hyponatremia (4%). RR was 58% and the median progression-free survival (PFS) was 7.5 months. The group with a treatment-free interval of 6 months or more tended to have better PFS than that with less than 6 months (p=0.01). The group with a platinum-free interval of 6 months or more had significantly better PFS than that with less than 6 months (p=0.09). Although the history of taxane usage was not relevant to prognosis, a taxane-free interval of 12 months or more was associated with a tendency for better PFS (p=0.06).
  
  
  CONCLUSIONS
  DP therapy was fully feasible and demonstrated efficacy for patients with recurrent endometrial cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Keio University School of Medicine, Shijunku-ku, Tokyo, Japan.
authors.forename: Tomomi
authors.initials: T
authors.lastname: Ninomiya
authors.affiliation: Department of Obstetrics and Gynecology, Keio University School of Medicine, Shijunku-ku, Tokyo, Japan gami@z8.keio.jp.
authors.forename: Wataru
authors.initials: W
authors.lastname: Yamagami
authors.affiliation: Department of Obstetrics and Gynecology, Keio University School of Medicine, Shijunku-ku, Tokyo, Japan.
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Susumu
authors.affiliation: Department of Obstetrics and Gynecology, Keio University School of Medicine, Shijunku-ku, Tokyo, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Makabe
authors.affiliation: Department of Obstetrics and Gynecology, Keio University School of Medicine, Shijunku-ku, Tokyo, Japan.
authors.forename: Kensuke
authors.initials: K
authors.lastname: Sakai
authors.affiliation: Department of Obstetrics and Gynecology, Keio University School of Medicine, Shijunku-ku, Tokyo, Japan.
authors.forename: Michiko
authors.initials: M
authors.lastname: Wada
authors.affiliation: Department of Obstetrics and Gynecology, Keio University School of Medicine, Shijunku-ku, Tokyo, Japan.
authors.forename: Aya
authors.initials: A
authors.lastname: Takigawa
authors.affiliation: Department of Obstetrics and Gynecology, Keio University School of Medicine, Shijunku-ku, Tokyo, Japan.
authors.forename: Tatsuyuki
authors.initials: T
authors.lastname: Chiyoda
authors.affiliation: Department of Obstetrics and Gynecology, Keio University School of Medicine, Shijunku-ku, Tokyo, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Nomura
authors.affiliation: Department of Obstetrics and Gynecology, Keio University School of Medicine, Shijunku-ku, Tokyo, Japan.
authors.forename: Fumio
authors.initials: F
authors.lastname: Kataoka
authors.affiliation: Department of Obstetrics and Gynecology, Keio University School of Medicine, Shijunku-ku, Tokyo, Japan.
authors.forename: Akira
authors.initials: A
authors.lastname: Hirasawa
authors.affiliation: Department of Obstetrics and Gynecology, Keio University School of Medicine, Shijunku-ku, Tokyo, Japan.
authors.forename: Kouji
authors.initials: K
authors.lastname: Banno
authors.affiliation: Department of Obstetrics and Gynecology, Keio University School of Medicine, Shijunku-ku, Tokyo, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Aoki
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D000077143:Docetaxel; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D001952:Bridged-Ring Compounds; D043823:Taxoids; D000077143:Docetaxel; C080625:taxane; D002945:Cisplatin
keywords: Endometrial cancer; cisplatin; docetaxel; recurrent